373 related articles for article (PubMed ID: 9128978)
1. CYFRA 21-1 is a useful marker for esophageal squamous cell carcinoma.
Yamamoto K; Oka M; Hayashi H; Tangoku A; Gondo T; Suzuki T
Cancer; 1997 May; 79(9):1647-55. PubMed ID: 9128978
[TBL] [Abstract][Full Text] [Related]
2. Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer.
Tas F; Aydiner A; Topuz E; Yasasever V; Karadeniz A; Saip P
J Exp Clin Cancer Res; 2000 Dec; 19(4):477-81. PubMed ID: 11277326
[TBL] [Abstract][Full Text] [Related]
3. Clinical usefulness of CYFRA 21-1 for esophageal squamous cell carcinoma in radiation therapy.
Wakatsuki M; Suzuki Y; Nakamoto S; Ohno T; Ishikawa H; Kiyohara H; Kiyozuka M; Shirai K; Nakayama Y; Nakano T
J Gastroenterol Hepatol; 2007 May; 22(5):715-9. PubMed ID: 17444861
[TBL] [Abstract][Full Text] [Related]
4. Assessment of serum CYFRA 21-1 in lung cancer.
Muraki M; Tohda Y; Iwanaga T; Uejima H; Nagasaka Y; Nakajima S
Cancer; 1996 Apr; 77(7):1274-7. PubMed ID: 8608502
[TBL] [Abstract][Full Text] [Related]
5. The significance of ferritin, lipid-associated sialic acid, CEA, squamous cell carcinoma (SCC) antigen, and CYFRA 21-1 levels in SCC of the head and neck.
Inal E; Laçin M; Asal K; Ceylan A; Köybaşioğlu A; Ileri F; Uslu SS
Kulak Burun Bogaz Ihtis Derg; 2004; 12(1-2):23-30. PubMed ID: 16010093
[TBL] [Abstract][Full Text] [Related]
6. Analysis of serum CYFRA 21-1 concentrations in patients with esophageal cancer.
Brockmann JG; St Nottberg H; Glodny B; Sprakel B; Senninger N
Anticancer Res; 2000; 20(6D):4899-904. PubMed ID: 11332443
[TBL] [Abstract][Full Text] [Related]
7. Study of a new tumor marker, CYFRA 21-1, in squamous cell carcinoma of the cervix, and comparison with squamous cell carcinoma antigen.
Tsai SC; Kao CH; Wang SJ
Neoplasma; 1996; 43(1):27-9. PubMed ID: 8843956
[TBL] [Abstract][Full Text] [Related]
8. Cytokeratin subunit 19 measured by CYFRA 21-1 assay in follow-up of cervical cancer.
Kainz C; Sliutz G; Mustafa G; Bieglmayr C; Koelbl H; Reinthaller A; Gitsch G
Gynecol Oncol; 1995 Mar; 56(3):402-5. PubMed ID: 7535720
[TBL] [Abstract][Full Text] [Related]
9. CYFRA 21-1 serum analysis in patients with esophageal cancer.
Brockmann JG; St Nottberg H; Glodny B; Heinecke A; Senninger NJ
Clin Cancer Res; 2000 Nov; 6(11):4249-52. PubMed ID: 11106239
[TBL] [Abstract][Full Text] [Related]
10. [A comparison of serum Cyfra 21-1 and SCC AG in the diagnosis of squamous cell esophageal carcinoma].
Ychou M; Khemissa-Akouz F; Kramar A; Senesse P; Grenier J
Bull Cancer; 2001 Oct; 88(10):1023-7. PubMed ID: 11713038
[TBL] [Abstract][Full Text] [Related]
11. Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen.
Bonfrer JM; Gaarenstroom KN; Korse CM; Van Bunningen BN; Kenemans P
Anticancer Res; 1997; 17(3C):2329-34. PubMed ID: 9245246
[TBL] [Abstract][Full Text] [Related]
12. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320
[TBL] [Abstract][Full Text] [Related]
13. Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study.
Ebert W; Dienemann H; Fateh-Moghadam A; Scheulen M; Konietzko N; Schleich T; Bombardieri E
Eur J Clin Chem Clin Biochem; 1994 Mar; 32(3):189-99. PubMed ID: 7518259
[TBL] [Abstract][Full Text] [Related]
14. CYFRA 21.1 in patients with cervical cancer: comparison with SCC and CEA.
Molina R; Filella X; Augé JM; Bosch E; Torne A; Pahisa J; Lejarcegui JA; Rovirosa A; Mellado B; Ordi J; Biete A
Anticancer Res; 2005; 25(3A):1765-71. PubMed ID: 16033097
[TBL] [Abstract][Full Text] [Related]
15. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
[TBL] [Abstract][Full Text] [Related]
16. Increased serum midkine concentration as a possible tumor marker in patients with superficial esophageal cancer.
Shimada H; Nabeya Y; Okazumi S; Matsubara H; Kadomatsu K; Muramatsu T; Ikematsu S; Sakuma S; Ochiai T
Oncol Rep; 2003; 10(2):411-4. PubMed ID: 12579281
[TBL] [Abstract][Full Text] [Related]
17. CYFRA 21-1 is not superior to SCC antigen and CEA in head and neck squamous cell cancer.
Wollenberg B; Jan V; Schmit UM; Hofmann K; Stieber P; Fateh-Moghadam A
Anticancer Res; 1996; 16(5B):3117-24. PubMed ID: 8920778
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of osteopontin in esophageal squamous cell carcinoma: comparison with common tumor markers.
Shimada Y; Watanabe G; Kawamura J; Soma T; Okabe M; Ito T; Inoue H; Kondo M; Mori Y; Tanaka E; Imamura M
Oncology; 2005; 68(2-3):285-92. PubMed ID: 16015046
[TBL] [Abstract][Full Text] [Related]
19. Can initial serum cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis?
Gaarenstroom KN; Kenter GG; Bonfrer JM; Korse CM; Van de Vijver MJ; Fleuren GJ; Trimbos JB
Gynecol Oncol; 2000 Apr; 77(1):164-70. PubMed ID: 10739706
[TBL] [Abstract][Full Text] [Related]
20. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Cataldo I; Sala M; Caldiera S; Bombardieri E
Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]